The I148M PNPLA3 variant mitigates Niacin beneficial effects: How the genetic screening in NAFLD patients gains value

被引：0
|
作者：
Paolini, E. [1 ,2 ]
Longo, M. [1 ,3 ]
Meroni, M. [1 ,4 ]
Malaspina, G. [1 ]
De Caro, E. R. [1 ]
Cespiati, A. [1 ,4 ]
Lombardi, R. [1 ,4 ]
Fracanzani, A. L. [1 ,4 ]
Dongiovanni, P. [1 ]
机构：
[1] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Gen Med & Metab Dis, Milan, Italy
[3] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[4] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Milan, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2021年 / 53卷
关键词：
D O I：
10.1016/j.dld.2020.12.074
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-35
引用
收藏
页码：S29 / S30
页数：4
相关论文
共 50 条
  • [41] ASSOCIATION BETWEEN PNPLA3 I148M POLYMORPHISM AND NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN THE INDIAN CONTINENT
    Rangegowda, D.
    Sharma, S.
    Kumar, K. N. Chandan
    Maiwal, R.
    Vashista, C.
    Sharma, M. K.
    Bhatia, V.
    Bhadoria, A. S.
    Rastogi, A.
    Sarin, S.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S748 - S748
  • [42] The rs738409 (I148M) Variant of the PNPLA3 Gene and Type 2 Diabetes in Yakutia
    Sydykova, Lubov A.
    Kurtanov, Khariton A.
    Borisova, Natalia V.
    Pavlova, Nadejda I.
    Stepanov, Konstantin M.
    Markova, Sardana V.
    Makarov, Albert D.
    Alekseeva, Sardana N.
    Antipina, Uliana D.
    INTERNATIONAL JOURNAL OF BIOMEDICINE, 2018, 8 (03) : 201 - 205
  • [43] PNPLA3 I148M Involved in Mechanism of Variability in Antilipogenesis Response to Exenatide
    Chen, Yunzhi
    Liang, Hua
    Xu, Fen
    DIABETES, 2020, 69
  • [44] PRIMARY HEPATOCELLULAR DAMAGE LOWERS ALCOHOL CONSUMPTION AND SUPPRESSES PERIPHERAL FAT MOBILIZATION IN ALD PATIENTS WITH GENETIC VARIANT I148M IN PNPLA3
    Rausch, V.
    Peccerella, T.
    Pawella, L.
    Lackner, K.
    Yagmur, E.
    Stickel, F.
    Herzig, S.
    Seitz, H. -K.
    Longerich, T.
    Straub, B.
    Mueller, S.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S772 - S772
  • [45] PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review
    Boeckmans, Joost
    Gatzios, Alexandra
    Schattenberg, Joern M.
    Koek, Ger H.
    Rodrigues, Robim M.
    Vanhaecke, Tamara
    LIVER INTERNATIONAL, 2023, 43 (05) : 975 - 988
  • [46] Mutant PNPLA3 I148M Protein as Pharmacological Target for Liver Disease
    Valenti, Luca
    Dongiovanni, Paola
    HEPATOLOGY, 2017, 66 (04) : 1026 - 1028
  • [47] PNPLA3 I148M POLYMORPHISM, ETIOLOGY, AND CLINICAL FEATURES OF HEPATOCELLULAR CARCINOMA
    Valenti, Luca
    Motta, Benedetta M.
    Bertelli, Cristina
    Sangiovanni, Angelo
    Rametta, Raffaela
    Dongiovanni, Paola
    Colombo, Massimo
    Fargion, Silvia
    Fracanzani, Anna Ludovica
    HEPATOLOGY, 2011, 54 : 1292A - 1292A
  • [48] PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease
    Speliotes, Elizabeth K.
    Schneider, Carolin Victoria
    LIVER INTERNATIONAL, 2025, 45 (03)
  • [49] PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients
    Nakaoka, Kazunori
    Hashimoto, Senju
    Kawabe, Naoto
    Nitta, Yoshifumi
    Murao, Michihito
    Nakano, Takuji
    Shimazaki, Hiroaki
    Kan, Toshiki
    Takagawa, Yuka
    Ohki, Masashi
    Kurashita, Takamitsu
    Takamura, Tomoki
    Nishikawa, Toru
    Ichino, Naohiro
    Osakabe, Keisuke
    Yoshioka, Kentaro
    SPRINGERPLUS, 2015, 4
  • [50] The PNPLA3 Variant Associated With Fatty Liver Disease (I148M) Accumulates on Lipid Droplets by Evading Ubiquitylation
    BasuRay, Soumik
    Smagris, Eriks
    Cohen, Jonathan C.
    Hobbs, Helen H.
    HEPATOLOGY, 2017, 66 (04) : 1111 - 1124
12345